Expertise in
9
conditions

Taishi Harada

Fukuchiyama, JP 
Expertise in
9
conditions
Fukuchiyama, JP 

Overview

Taishi Harada practices practicing medicine in Fukuchiyama, Japan.

Mr. Harada is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Pancreaticoduodenectomy, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 148 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Fukuchiyama, Japan
Other Locations
Kitakyushu, Japan
Fukuoka, Japan
Wako, 3510198, Japan
Osaka, Japan
Kyoto, 6068502, Japan
Koriyama, Japan
Chikushino-shi, Japan
Japan
Kita, Japan
Izumi, Japan
Sendai, 9808577, Japan
Sapporo, Japan
Higashi, 8128582, Japan
Yamaguchi, Japan
Yokohama, 2410815, Japan
Bunkyo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3

148 Total Publications

Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC.
Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC.
Journal: International journal of clinical oncology
Published: April 21, 2026

Frequently Asked Questions about Taishi Harada

Is Taishi Harada a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Taishi Harada is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Taishi Harada participate in research or clinical trials?

Yes. Taishi Harada has published 148 articles and abstracts on conditions like Lung Cancer. You can view a list of Taishi Harada's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Harada's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile